Satvat Ali J. 4

What Happened
Satvat Ali J., a director of BridgeBio Pharma, received equity awards on June 22, 2026. The Form 4 reports acquisition of 3,990 restricted stock units (RSUs) and 5,277 RSUs reported as derivative instruments, each at $0.00 per unit (total reported value $0). According to the filing, these RSUs vest in full on June 22, 2027, contingent on the Reporting Person’s continued board service through that date.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (appears timely).
• Grants: 3,990 RSUs (acquired) + 5,277 RSUs (derivative) = 9,267 RSU units total. Price reported: $0.00 per unit; total reported consideration $0.
• Vesting: All RSUs vest in full on June 22, 2027, subject to continued service (Footnotes F1–F3).
• Footnotes: F1 – RSUs granted under the 2021 Plan; F2 – each RSU represents a contingent right to one share; F3 – vesting condition reiterated.
• Shares owned after transaction: not specified in the information provided.
• Filing remarks: Exhibit 24 — Power of Attorney included.

Context
This was an award/grant of RSUs (transaction code A), not an open-market purchase or sale. RSUs are a form of compensation that convert into shares only if vesting conditions are met; no shares were delivered or sold at grant and no immediate market signal (buy/sell) resulted from this filing.